Shots:
- The STOP-COVID study was conducted with a research collaboration b/w Pfizer & an ARO in Brazil, evaluating the efficacy & safety of tofacitinib (10mg, bid) + SoC vs PBO + SoC in a ratio (1:1) in 289 hospitalized patients with COVID-19 pneumonia who were not on ventilation for 14 days or until hospital discharge
- The 1EP of trial demonstrates a lower cumulative incidence of death or respiratory failure (18.1% vs 29.0%) @ 28 days, death from any cause (2.8% & 5.5%) @28 day
- Tofacitinib is not approved or authorized for COVID-19 patients & not used in patients with an active serious infection. The therapy is approved in the US in 4 indications for active RA, active PsA, UC & active pcJIA
Click here to read full press release/ article | Ref: Business Wire | Image: The Wall Street Journal
The post Pfizer Presents Results of Tofacitinib in STOP-COVID Study for Patients Hospitalized with COVID-19 Pneumonia at NEJM first appeared on PharmaShots.
